Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment



Summary

Immune-checkpoint targeting drug conjugates (ICT-DCs) represent a promising new strategy in cancer treatment. These conjugates combine the precision of immune checkpoint inhibitors (ICIs) with the potency of cytotoxic drugs. By targeting ICIs to tumor cells or the tumor microenvironment, ICT-DCs aim to enhance ICI activity, reduce systemic toxicity, and overcome resistance mechanisms. This approach allows for targeted delivery of the drug payload directly to cancer cells, boosting anti-tumor immunity while minimizing off-target effects. ICT-DCs have shown encouraging preclinical results and are entering clinical trials, offering potential improvements in cancer therapy compared to traditional ICIs and chemotherapy.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!